Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia is developing antibodies against IL1RAP. Interim data from its Phase IIa CANFOUR trial, investigating CAN04 (anti-IL1RAP) in first-line on-small cell lung cancer (NSCLC) and PDAC, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view. Final analysis and key efficacy data are expected during 2021. In February 2021 the first PDAC patient started treatment in the extension part of the CANFOUR study. Cantargia is preparing to engage with regulators to discuss Phase III development plans. In March, Novartis reported negative headline data from its Phase III CANOPY-2 trial, investigating canakinumab (anti-IL1beta) with docetaxel for 2nd/3rd-line NSCLC, a potential competitor to CAN04, which has created some negative sentiment, although we view CAN04 as clearly differentiated from canakinumab.
Increasing the understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.